We propose to target the survival signaling machinery as the secondary “Achilles’ heel” in the early adaptive drug persister tumor cells in combination with EGFR-TKIs to more effectively eradicate the minimal residual drug persister tumor cells. Here, EGFR is linked to neoplasm.